Stopfer LE, Rettko NJ, Leddy O, Mesfin JM, Brown E, Winski S, Bryson B, Wells JA, White FM.  2022.  MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas.. Proc Natl Acad Sci U S A. 119(49):e2208900119.

Gerosa L, Chidley C, Fröhlich F, Sanchez G, Lim SKyun, Muhlich J, Chen J-Y, Vallabhaneni S, Baker GJ, Schapiro D et al..  2020.  Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.. Cell Syst. 11(5):478-494.e9.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.  2018.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.. Drug Metab Dispos. 46(5):658-666.

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF.  2017.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res. 123:10-25.